Scientists find hidden ‘off switch’ that controls cell identity

Australian researchers have identified how cells silence the genes they do not need, a finding that could open new paths in cancer treatment and regenerative medicine. 

Every cell in your body carries the same genetic blueprint. A neuron and a liver cell share identical DNA, yet they look different, behave differently, and do entirely different jobs. How cells resolve that identity crisis – using one instruction manual to build thousands of specialised parts – has been one of biology’s more intriguing questions. 

Now, scientists at the Australian Regenerative Medicine Institute (ARMI) and the Biomedicine Discovery Institute (BDI) at Monash University have identified a key part of the answer. 

The ​​research, published in Molecular Cell, ​​discovered how cells decide how strongly to silence genes that are required for controlling cell identity​. The team,​​ led by ARMI’s Professor Edwina McGlinn and BDI’s Professor Chen Davidovich, pinpointed the molecular machinery responsible, and demonstrated that adjusting it can shift which genes a cell expresses, ​without ​changing the DNA itself​​.​​​ 

Hox genes and the body’s biological coordinates 

The study centred on a cluster of genes called Hox genes. Professor McGlinn works with these genes and explained that they act as coordinates for the body’s head-to-tail axis in the developing embryo – directing which structures form where, and when.  

“Hox genes occur in a linear sequence – next to each other – on the same chromosome,” Professor McGlinn said. “Their linear order on the chromosome matches the order in which they act when forming the head-to-tail body axis.” 

Mutations in Hox genes first gained scientific attention through fruit fly research more than 40 years ago, producing dramatic alterations to body structure. That work eventually earned a Nobel Prize. Since then, researchers have mapped similar gene clusters involved in organ development, including Pax genes, which guide the formation of eyes and sensory organs. 

But genes alone do not tell the full story. 

“Cells destined to become a certain body or organ type must draw on ​only a subset of ​body-plan genes that are essential to forming that structure,” Professor McGlinn said. “However, all cells contain the same full suite ​​of body plan genes. That means cells must switch off body-plan genes that would otherwise send them in the ​wrong direction​. That ‘off switch’ is the mechanism we examined in our latest study.” 

How PRC2 controls gene silencing in developing cells 

The control mechanism the ARMI/BDI team investigated is epigenetic, meaning it operates above the level of the DNA sequence itself. Enzymes attach or remove chemical tags, called methyl groups, to DNA and to the proteins around which DNA is wound. When enough of these tags accumulate, the DNA in that region compresses into a structure called heterochromatin, and the genes inside go silent. 

Professor Davidovich, who co-led the research, describes how gene silencing works in practice. 

​​​“​For ge​nes to be repressed over a long period of time, cells have to mark them in a certain way, so they will not be confused with genes that need to be active.” he said. “This mark, called methylation, is​​ written by a protein complex called Polycomb Repressive Complex 2 (PRC2).” 

The team made targeted changes to PRC2 activity, altering how it reads and modifies chromatin. Cells responded by shifting ​​​the timing of ​their Hox gene expression – not because the genes changed, but because the silencing mechanism did. 

Implications for cancer treatment and regenerative medicine 

This research increases our understanding of cellular growth and repair, having implications for the development of advanced cancer therapies and regenerative medicine. 

In cancer, cells progressively lose their​ original​ identity. They stop behaving like the tissue they came from and start dividing without the normal constraints. Understanding the epigenetic machinery that maintains cell identity could offer new ways to interrupt that process. 

In regenerative medicine, the findings ​​may open paths to reactivate​​ the biological instructions that build healthy tissue using the body’s own developmental logic, rather than working against it. 

Professor McGlinn said the research does not yet point to a specific therapy. But it does identify a class of molecular controls that work epigenetically to fine-tune cell identity and the timing of developmental events. 

“Ultimately, it’s about learning to work with how cells make healthy bodies,” Professor McGlinn says. “There are opportunities here for subtler, more refined therapeutics.” 

Funding for this research was provided by the Australian Government Department of Education, the National Health and Medical Research Council of Australia, the Australian Research Council and the Victorian Government. 

About ARMI
The Australian Regenerative Medicine Institute (ARMI), based at Monash University in Melbourne, is a world leader in regenerative biology and stem cell research. ARMI works at the frontier of science, translating discovery into hope for people living with conditions like cancer, arthritis, dementia, neurodegenerative disease, rare disease and injury.

Media Contact:
Penny Fannin, Communications Consultant, ARMI
M: +61 (0) 417125700
E: penny.fannin@monash.edu